Inflammatory and Metabolic Syndrome Biomarker Analysis of Vascular Outcomes in End-stage Renal Disease

Sweigert, Patrick J.; Bansal, Vinod; Hoppensteadt, Debra; Saluk, Jennifer; Syed, Daneyal; Fareed, Jawed

doi:10.1055/s-0036-1593409

Cited by 8 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Qin et al described that decreased leptin levels were an independent risk factor for LVH development in patients on hemodialysis [ 112 ]. Curiously, in ESRD, patients with a history of stroke presented higher leptin levels than those without stroke history, while patients with congestive heart failure showed lower leptin values that those without history of congestive heart failure [ 113 ].…”

Section: Leptinmentioning

confidence: 99%

New Insights into Adiponectin and Leptin Roles in Chronic Kidney Disease

et al. 2022

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is commonly associated with a high burden of comorbidities and poor clinical outcomes. Malnutrition–inflammation–atherosclerosis syndrome is common in the more severe stages of CKD, suggesting a close interplay for these three comorbid conditions. Both malnutrition and obesity are associated with a disturbed adipokine profile and inflammation, contributing to a higher risk of cardiovascular disease (CVD) events. Adiponectin and leptin have important roles in carbohydrate and lipid metabolism, and in the inflammatory process. The effects of adiponectin and leptin alterations in CKD, which are usually increased, and their association with the different comorbidities found in CKD, will be focused on to understand their crosstalk with the risk of CVD events. Nonetheless, although adiponectin and leptin contribute to a higher risk of CVD events, further studies are warranted to fully clarify their roles, especially when different comorbidities exist.

show abstract

Section: Leptinmentioning

confidence: 99%

New Insights into Adiponectin and Leptin Roles in Chronic Kidney Disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“… 16 , 17 Furthermore, this elevation has also shown to be associated with the progression of CKD to ESRD with higher rates of cardiovascular complications and mortality in this patient group. 17 – 20 Interestingly, major improvements were observed at the levels of inflammatory biomarkers after kidney transplantation; this has indicated that inflammation is not only a cause but also a consequence in the development of a kidney disease and its associated complications. 21 Regarding this, several dialysis-related factors have been associated with persistent and low-grade inflammation in ESRD.…”

Section: Introductionmentioning

confidence: 99%

The Relevance of Thrombo-Inflammatory Biomarkers and Their Relationship with Circulating Glycosaminoglycans in End-Stage Renal Disease Patients

Allen

Bansal

Siddiqui

et al. 2023

Clin Appl Thromb Hemost

Self Cite

View full text Add to dashboard Cite

En-stage renal disease (ESRD) is a growing public health problem. The atherosclerotic cardiovascular complications are the leading causes of mortality and morbidity in the ESRD. In this study, we sought to quantify the levels of thrombo-inflammatory biomarkers in an ESRD patients in comparison to healthy controls to determine their relevance in thrombo-inflammation and adverse outcomes. The levels of D-Dimer, C-reactive protein (CRP), plasminogen activator inhibitor 1 (PAI-1) antigen, functional PAI-1, thrombin activatable fibrinolysis inhibitor, tissue plasminogen activator, von Willebrand factor, and anti-PF4 IgG and microparticle (MP) activity were quantified by using commercially available ELISA immunoassays for each of the ESRD ( n = 73) and control plasma samples ( n = 10). The levels of endogenous glycosaminoglycans (GAGs) were quantified by utilizing a Heparin Red Probe (Redprobes UG, Germany). The collected data were analyzed to demonstrate the relationship between various parameters. All the tested biomarkers were increased in ESRD patients in comparison to healthy controls ( p < 0.05). These biomarkers have shown significant correlations within each other except for anti-PF4 Ig G and MPs. The CRP levels were significantly higher in patients who had coronary artery disease (CAD) ( p < 0.05), but there was no significant difference in other biomarkers according to the cardiovascular outcomes. In the multivariate analysis, the CRP (odds ratio: 1.19; 95% confidence interval: 1.01–1.41; p: 0.03) value was an independent predictor of CAD. In this study, we demonstrated increased levels of 10 different biomarkers in ESRD patients. The CRP levels can be a good predictor of CAD in ESRD patients.

show abstract

“…Decreased leptin levels were also associated with a higher risk of CV events in hemodialysis patients and was also considered an independent risk factor for LVH development [ 19 ]. Interestingly, in ESKD, while patients with a history of stroke presented higher leptin levels than those without a stroke history, patients with congestive heart failure showed lower leptin than those without a history of congestive heart failure [ 20 ]. Given the controversial data, further studies are warranted to fully clarify leptin’s role, namely, its association with morbidity and mortality risks and its contribution to LVH development in CKD and, especially, in ESKD.…”

Section: Introductionmentioning

confidence: 99%

The Association of Leptin with Left Ventricular Hypertrophy in End-Stage Kidney Disease Patients on Dialysis

et al. 2023

View full text Add to dashboard Cite

Left ventricular hypertrophy (LVH) is a common cardiovascular complication in end-stage kidney disease (ESKD) patients. We aimed at studying the association of LVH with adiponectin and leptin levels, cardiovascular stress/injury biomarkers and nutritional status in these patients. We evaluated the LV mass (LVM) and calculated the LVM index (LVMI) in 196 ESKD patients on dialysis; the levels of hemoglobin, calcium, phosphorus, parathyroid hormone, albumin, adiponectin, leptin, N-terminal pro B-type natriuretic peptide (NT-proBNP) and growth differentiation factor (GDF)-15 were analyzed. ESKD patients with LVH (n = 131) presented higher NT-proBNP and GDF-15, lower hemoglobin and, after adjustment for gender, lower leptin levels compared with non-LVH patients. LVH females also showed lower leptin than the non-LVH female group. In the LVH group, LVMI presented a negative correlation with leptin and a positive correlation with NT-proBNP. Leptin emerged as an independent determinant of LVMI in both groups, and NT-proBNP in the LVH group. Low hemoglobin and leptin and increased calcium, NT-proBNP and dialysis vintage are associated with an increased risk of developing LVH. In ESKD patients on dialysis, LVH is associated with lower leptin values (especially in women), which are negatively correlated with LVMI, and with higher levels of biomarkers of myocardial stress/injury. Leptin and NT-proBNP appear as independent determinants of LVMI; dialysis vintage, hemoglobin, calcium, NT-proBNP and leptin emerged as predicting markers for LVH development. Further studies are needed to better understand the role of leptin in LVH in ESKD patients.

show abstract

Inflammatory and Metabolic Syndrome Biomarker Analysis of Vascular Outcomes in End-stage Renal Disease

Cited by 8 publications

References 19 publications

New Insights into Adiponectin and Leptin Roles in Chronic Kidney Disease

New Insights into Adiponectin and Leptin Roles in Chronic Kidney Disease

The Relevance of Thrombo-Inflammatory Biomarkers and Their Relationship with Circulating Glycosaminoglycans in End-Stage Renal Disease Patients

The Association of Leptin with Left Ventricular Hypertrophy in End-Stage Kidney Disease Patients on Dialysis

Contact Info

Product

Resources

About